Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2010

Kim Dong Hwan Dennis, Kong Jee Hyun, Byeun Ji Young, Jung Chul Won, Xu Wei, Liu Xiangdong, Kamel-Reid Suzanne, Kim Yeo-Keyoung, Kim Hyeoung-Joon, Lipton Jeffrey H

Abstract excerpt

PURPOSE: The present study analyzed treatment outcomes of imatinib therapy by interindividual genetic variants in candidate biological pathways of chronic myeloid leukemia (CML) such as apoptosis, angiogenesis, IFN-γ signaling pathways, or drug transport/metabolism of imatinib. EXPERIMENTAL DESIG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Diagnostic Techniques

Share to Piperazines

Share to Pyrimidines

Source

Identifiers

PMID: 20959405
DOI: 10.1158/1078-0432.CCR-10-1638

Genes

IFNG
FAS
ABCG2
IFNGR2
JAK3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-20959405-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.PMID 20959405Read ↗

Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.Semantic proximity Read ↗

Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemiaSemantic proximity Read ↗

Association of Interferon Gamma +874T/A Polymorphism and Leukemia Risk: A Meta-Analysis.Semantic proximity Read ↗

Pharmacogenomic Analysis of Cytogenetic Response in Chronic Myeloid Leukemia Patients Treated with ImatinibSemantic proximity Read ↗

Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).Semantic proximity Read ↗

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.Semantic proximity Read ↗

Immune-Related Genes for the Prediction of Response to Imatinib therapy in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Semantic proximity Read ↗

The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.Semantic proximity Read ↗

Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.Semantic proximity Read ↗

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.Semantic proximity Read ↗

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.